Pharmacotherapeutics to Restore Neurological Function Compromised by Central Demyelination
Received Date: Apr 19, 2023 / Published Date: Jun 27, 2023
Abstract
The multiple sclerosis and Parkinson’s complaint are neurodegenerative complaint which effect on the central nervous system. Which loss the collaboration between brain and body multiple sclerosis is the progressive, autoimmune complaint. It occurs when your vulnerable system attack myelin cell in your brain and spinal cord. Parkinson’s complaint is caused by the loss of dopamine in a part of your brain called substantial nigra, which causes and cure are unknown. MS complaint are generally occurs in youthful adult i.e. 20 to 40 times where as Parkinson’s complaint generally occurs in old persons i.e. 60 times. Both the complaint don't do in same person, both complaint loss the collaboration of brain and body related to gait dysfunction. Dalfampridine is one of the available treatments for to ameliorate the walking in MS and Parkinson’s complaint related to gait dysfunction. Dalfampridine is the oral potassium channel blocker which was lately approved by FDA for sympathomimetic treatment in MS. Dalfampridine which acts on central and supplemental nervous system enhances conduction in demyelinated axon and improves waking capability of MS case.
Citation: Sheikh T (2023) Pharmacotherapeutics to Restore Neurological Function Compromised by Central Demyelination. J Pharmacokinet Exp Ther 7: 206.
Copyright: © 2023 Sheikh T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Share This Article
黑料网 Journals
Article Usage
- Total views: 477
- [From(publication date): 0-2023 - Nov 23, 2024]
- Breakdown by view type
- HTML page views: 413
- PDF downloads: 64